Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000934
Chunk: 39

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 39
---
 that the
SEC is currently contemplating terminating such registration. The issued and outstanding shares of Depositary Shares are listed and admitted
for trading on the Principal Market, and the Company is in compliance in all material respects with the current listing requirements of
the Principal Market; and the Securities will be listed and admitted for trading on the Principal Market at or prior to Commencement,
with respect to any Commitment Shares, and prior to the time of sale to the Investor pursuant to this Agreement, with respect to the Purchase
Shares. Except as disclosed in the SEC Documents, the Company has not, in the twelve (12) months preceding the Execution Date, received
any notice from the Principal Market to the effect that the Company is not in compliance with the listing or maintenance requirements
of the Principal Market. Except as disclosed in the SEC Documents, the Company is, and currently has no reason to believe that it will
not in the reasonably foreseeable future continue to be, in compliance with all such listing and maintenance requirements.

(z) .
As of the Execution Date, the Company’s accounting firm is PKF Littlejohn LLP. To the knowledge of the Company, such accounting firm is a registered public accounting firm as required by the Exchange Act.

(aa) . The
Company has not, and to its knowledge no Person acting on its behalf has, (i) taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.

(bb) .
The Company is not currently, and to its knowledge has never been, an issuer identified in Rule 144(i)(1) under the Securities Act.

(cc) Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.

(dd). The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended.

(ee) .